华东医药最新公告：全资子公司司美格鲁肽注射液上市申请获受理

证券之星04-14

华东医药(000963.SZ)公告称，公司全资子公司杭州中美华东制药江东有限公司收到国家药监局签发的《受理通知书》，其申报的司美格鲁肽注射液(研发代码：HDM1702)用于成人患者长期体重管理的上市许可申请获得受理。该药物为长效GLP-1受体激动剂，此前已完成体重管理适应症Ⅲ期临床研究，结果显示与原研药疗效相当且安全性良好。截至目前，公司在该项目(体重管理适应症)的研发直接投入总金额约为8551万元。本次申请获受理是产品研发的重要里程碑，有助于提升公司在内分泌治疗领域的核心竞争力。鉴于药品审评审批时间及结果存在不确定性，敬请投资者注意投资风险。

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

相关 ETF

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2627441796?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-14 18:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627441796","market":"sh","top_or_hot":-1,"title":"华东医药最新公告：全资子公司司美格鲁肽注射液上市申请获受理","media":"证券之星","content":"<html><body><p><a href=\"https://laohu8.com/S/000963\">华东医药</a>(000963.SZ)公告称，公司全资子公司杭州中美华东制药江东有限公司收到国家药监局签发的《受理通知书》，其申报的司美格鲁肽注射液(研发代码：HDM1702)用于成人患者长期体重管理的上市许可申请获得受理。该药物为长效GLP-1受体激动剂，此前已完成体重管理适应症Ⅲ期临床研究，结果显示与原研药疗效相当且安全性良好。截至目前，公司在该项目(体重管理适应症)的研发直接投入总金额约为8551万元。本次申请获受理是产品研发的重要里程碑，有助于提升公司在内分泌治疗领域的核心竞争力。鉴于药品审评审批时间及结果存在不确定性，敬请投资者注意投资风险。</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p><h2>相关 ETF</h2><p><img src=\"https://static.stockstar.com/etf/51201020260414.png\"/><img src=\"https://static.stockstar.com/etf/51608020260414.png\"/></p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华东医药最新公告：全资子公司司美格鲁肽注射液上市申请获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华东医药最新公告：全资子公司司美格鲁肽注射液上市申请获受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-14 18:31 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026041400031020.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>华东医药(000963.SZ)公告称，公司全资子公司杭州中美华东制药江东有限公司收到国家药监局签发的《受理通知书》，其申报的司美格鲁肽注射液(研发代码：HDM1702)用于成人患者长期体重管理的上市许可申请获得受理。该药物为长效GLP-1受体激动剂，此前已完成体重管理适应症Ⅲ期临床研究，结果显示与原研药疗效相当且安全性良好。截至目前，公司在该项目(体重管理适应症)的研发直接投入总金额约为8551...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026041400031020.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1969619763.USD","symbol_name":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"https://stock.stockstar.com/RB2026041400031020.shtml","article_id":"2627441796","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627441796","pubTimestamp":1776162678,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"华东医药公告称，公司全资子公司杭州中美华东制药江东有限公司收到国家药监局签发的《受理通知书》，其申报的司美格鲁肽注射液用于成人患者长期体重管理的上市许可申请获得受理。截至目前，公司在该项目的研发直接投入总金额约为8551万元。本次申请获受理是产品研发的重要里程碑，有助于提升公司在内分泌治疗领域的核心竞争力。鉴于药品审评审批时间及结果存在不确定性，敬请投资者注意投资风险。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0196":"行业龙头","BK0175":"白马股","000963":"华东医药","BK0187":"一线龙头","BK0183":"MSCI概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0132":"高送转概念","BK0209":"零售","BK0188":"融资融券"},"translate_title":"Huadong Medicine's latest announcement: The listing application of semaglutide injection, a wholly-owned subsidiary, was accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000963":1.5},"content_text":"华东医药(000963.SZ)公告称，公司全资子公司杭州中美华东制药江东有限公司收到国家药监局签发的《受理通知书》，其申报的司美格鲁肽注射液(研发代码：HDM1702)用于成人患者长期体重管理的上市许可申请获得受理。该药物为长效GLP-1受体激动剂，此前已完成体重管理适应症Ⅲ期临床研究，结果显示与原研药疗效相当且安全性良好。截至目前，公司在该项目(体重管理适应症)的研发直接投入总金额约为8551万元。本次申请获受理是产品研发的重要里程碑，有助于提升公司在内分泌治疗领域的核心竞争力。鉴于药品审评审批时间及结果存在不确定性，敬请投资者注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627441796","isCrawlerRequest":true}